These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14663603)

  • 21. Lipoprotein(a). The bad cholesterol.
    Habib SS
    Saudi Med J; 2004 Apr; 25(4):429-33. PubMed ID: 15083210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is lipoprotein (a)-apheresis useful?
    Bambauer R
    Ther Apher Dial; 2005 Apr; 9(2):142-7. PubMed ID: 15828926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-density lipoprotein apheresis is effective in reducing lipoprotein(a) levels and in improving symptoms in a patient with refractory angina secondary to accelerated coronary artery disease.
    Ibrahim M; Ussen B; Pottle A; Barbir M
    J Clin Lipidol; 2012; 6(2):192-4. PubMed ID: 22385553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lipoprotein (a), a cardiovascular risk factor: importance of its determination in current clinical practice].
    Couderc R; Maachi M
    J Mal Vasc; 1998 Jun; 23(3):165-75. PubMed ID: 9669219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management.
    Keller C
    Ther Apher Dial; 2007 Feb; 11(1):2-8. PubMed ID: 17309568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated Lp(a) with a small apo(a) isoform in children: risk factor for the development of premature coronary artery disease.
    Dirisamer A; Widhalm H; Aldover-Macasaet E; Molzer S; Widhalm K
    Acta Paediatr; 2008 Dec; 97(12):1653-7. PubMed ID: 18684164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipoprotein(a) as a marker for coronary heart disease.
    Duriez P; Dallongeville J; Fruchart JC
    Br J Clin Pract Suppl; 1994 Dec; (77):51-8. PubMed ID: 19496273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [LDL-Apheresis for the treatment of hyperchylomicronemia-induced pancreatitis].
    Sattler AM; Bock K; Schmidt S; Maisch B; Schaefer JR
    Z Kardiol; 2003; 92(Suppl 3):III64-7. PubMed ID: 14663605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shear stress-dependent platelet function after LDL cholesterol apheresis.
    Spieker LE; Ruschitzka F; Badimon JJ; Noll G; Corti R
    Thromb Res; 2004; 113(6):395-8. PubMed ID: 15226094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased cerebral CO(2) reactivity after heparin-mediated extracorporal LDL precipitation (HELP) in patients with coronary heart disease and hyperlipidemia.
    Pfefferkorn TK; Knüppel HP; Jaeger BR; Thiery J; Hamann GF
    Stroke; 1999 Sep; 30(9):1802-6. PubMed ID: 10471427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].
    Schettler VJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P; ;
    Internist (Berl); 2016 May; 57(5):511-6. PubMed ID: 27118008
    [No Abstract]   [Full Text] [Related]  

  • 33. Lipid apheresis techniques: current status in Germany.
    Grützmacher P; Kleinert C
    Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):20-3. PubMed ID: 22911177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors.
    Orsó E; Ahrens N; Kilalić D; Schmitz G
    Atheroscler Suppl; 2009 Dec; 10(5):74-8. PubMed ID: 20129380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.
    Bilgen D; Sönmez H; Ekmekçi H; Ulutin T; Oztürk Z; Kökoğlu E; Bayram C; Soner A; Domaniç N
    Clin Biochem; 2005 Jan; 38(1):92-6. PubMed ID: 15607324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Electroelution of lipoprotein(a) [Lp(a)] from native polyacrylamide gels: a new, simple method to purify Lp(a).
    Chellan B; Appukuttan PS; Jayakumari N
    J Biochem Biophys Methods; 2006 Jul; 68(1):43-53. PubMed ID: 16677712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.
    Longenecker JC; Klag MJ; Marcovina SM; Liu YM; Jaar BG; Powe NR; Fink NE; Levey AS; Coresh J
    J Am Soc Nephrol; 2005 Jun; 16(6):1794-802. PubMed ID: 15800123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome.
    Berneis K; Rizzo M; Hersberger M; Rini GB; Di Fede G; Pepe I; Spinas GA; Carmina E
    Int J Clin Pract; 2009 Jan; 63(1):56-62. PubMed ID: 19125993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
    Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
    J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models.
    Boffa MB; Marcovina SM; Koschinsky ML
    Clin Biochem; 2004 May; 37(5):333-43. PubMed ID: 15087247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.